CL2022001495A1 - Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-cd20 x anti-cd3. - Google Patents
Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-cd20 x anti-cd3.Info
- Publication number
- CL2022001495A1 CL2022001495A1 CL2022001495A CL2022001495A CL2022001495A1 CL 2022001495 A1 CL2022001495 A1 CL 2022001495A1 CL 2022001495 A CL2022001495 A CL 2022001495A CL 2022001495 A CL2022001495 A CL 2022001495A CL 2022001495 A1 CL2022001495 A1 CL 2022001495A1
- Authority
- CL
- Chile
- Prior art keywords
- bispecific antibodies
- formulations containing
- human
- stabilized formulations
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946207P | 2019-12-10 | 2019-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001495A1 true CL2022001495A1 (es) | 2023-01-13 |
Family
ID=74141846
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001495A CL2022001495A1 (es) | 2019-12-10 | 2022-06-07 | Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-cd20 x anti-cd3. |
| CL2024001536A CL2024001536A1 (es) | 2019-12-10 | 2024-05-22 | Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-cd20 x anti-cd3. |
| CL2024003444A CL2024003444A1 (es) | 2019-12-10 | 2024-11-11 | Formulación farmacéutica líquida estable que comprende un anticuerpo biespecífico anti-cd20/cd3 humano. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001536A CL2024001536A1 (es) | 2019-12-10 | 2024-05-22 | Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-cd20 x anti-cd3. |
| CL2024003444A CL2024003444A1 (es) | 2019-12-10 | 2024-11-11 | Formulación farmacéutica líquida estable que comprende un anticuerpo biespecífico anti-cd20/cd3 humano. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20210206870A1 (https=) |
| EP (1) | EP4072585A1 (https=) |
| JP (2) | JP7813703B2 (https=) |
| KR (1) | KR20220113417A (https=) |
| CN (1) | CN115003331A (https=) |
| AU (1) | AU2020402030A1 (https=) |
| BR (1) | BR112022011150A2 (https=) |
| CA (1) | CA3161059A1 (https=) |
| CL (3) | CL2022001495A1 (https=) |
| CO (1) | CO2022008684A2 (https=) |
| IL (1) | IL293372A (https=) |
| MY (1) | MY210570A (https=) |
| PH (1) | PH12022551275A1 (https=) |
| TW (1) | TW202135860A (https=) |
| WO (1) | WO2021119135A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202400228A (zh) | 2022-02-25 | 2024-01-01 | 美商再生元醫藥公司 | 減輕細胞激素釋放症候群的給藥方案 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| JP2007526220A (ja) * | 2003-06-05 | 2007-09-13 | ジェネンテック・インコーポレーテッド | Ｂ細胞疾患の併用療法 |
| WO2009070642A1 (en) * | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
| JP2012041317A (ja) * | 2010-08-23 | 2012-03-01 | Panasonic Corp | フェロセン修飾抗体 |
| PT2691112T (pt) * | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| IL263466B2 (en) * | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| KR102614189B1 (ko) * | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
| AU2016378573A1 (en) * | 2015-12-22 | 2018-07-19 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-CD20/anti-CD3 antibodies to treat acute lymphoblastic leukemia |
| TWI865430B (zh) | 2017-07-24 | 2024-12-11 | 美商再生元醫藥公司 | 穩定化之抗體組合物及其製法 |
| KR20200037863A (ko) * | 2017-08-25 | 2020-04-09 | 오메로스 코포레이션 | 고도로 농축된 저점도 masp-2 억제 항체 제제, 키트, 및 비정형 용혈성 증후군을 앓고 있는 대상체의 치료 방법 |
| AU2022214319A1 (en) * | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
-
2020
- 2020-12-08 TW TW109143208A patent/TW202135860A/zh unknown
- 2020-12-09 KR KR1020227021715A patent/KR20220113417A/ko active Pending
- 2020-12-09 PH PH1/2022/551275A patent/PH12022551275A1/en unknown
- 2020-12-09 CN CN202080092885.6A patent/CN115003331A/zh active Pending
- 2020-12-09 AU AU2020402030A patent/AU2020402030A1/en active Pending
- 2020-12-09 JP JP2022535058A patent/JP7813703B2/ja active Active
- 2020-12-09 BR BR112022011150A patent/BR112022011150A2/pt unknown
- 2020-12-09 IL IL293372A patent/IL293372A/en unknown
- 2020-12-09 US US17/116,699 patent/US20210206870A1/en not_active Abandoned
- 2020-12-09 WO PCT/US2020/064025 patent/WO2021119135A1/en not_active Ceased
- 2020-12-09 CA CA3161059A patent/CA3161059A1/en active Pending
- 2020-12-09 EP EP20838711.8A patent/EP4072585A1/en active Pending
- 2020-12-09 MY MYPI2022003031A patent/MY210570A/en unknown
-
2022
- 2022-06-07 CL CL2022001495A patent/CL2022001495A1/es unknown
- 2022-06-22 CO CONC2022/0008684A patent/CO2022008684A2/es unknown
-
2024
- 2024-05-22 CL CL2024001536A patent/CL2024001536A1/es unknown
- 2024-11-11 CL CL2024003444A patent/CL2024003444A1/es unknown
-
2025
- 2025-04-07 US US19/171,676 patent/US20250236677A1/en active Pending
- 2025-10-17 JP JP2025175127A patent/JP2026016480A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022551275A1 (en) | 2024-01-08 |
| US20250236677A1 (en) | 2025-07-24 |
| KR20220113417A (ko) | 2022-08-12 |
| CN115003331A (zh) | 2022-09-02 |
| CL2024001536A1 (es) | 2024-10-18 |
| CL2024003444A1 (es) | 2025-04-11 |
| TW202135860A (zh) | 2021-10-01 |
| MY210570A (en) | 2025-09-30 |
| US20210206870A1 (en) | 2021-07-08 |
| CA3161059A1 (en) | 2021-06-17 |
| EP4072585A1 (en) | 2022-10-19 |
| JP2023507561A (ja) | 2023-02-24 |
| JP2026016480A (ja) | 2026-02-03 |
| BR112022011150A2 (pt) | 2022-08-23 |
| WO2021119135A1 (en) | 2021-06-17 |
| IL293372A (en) | 2022-07-01 |
| AU2020402030A1 (en) | 2022-07-28 |
| JP7813703B2 (ja) | 2026-02-13 |
| CO2022008684A2 (es) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019011021A2 (es) | Formulacion estable de anticuerpos | |
| UY33169A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) | |
| CY1126062T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| MX2025010757A (es) | Formulacion farmaceutica de ph bajo | |
| EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
| MX2020007697A (es) | Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra grupo de diferenciacion 3 (cd3) y grupo de diferenciacion 20 (cd20) y sus usos. | |
| MX2019008084A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). | |
| CL2017001115A1 (es) | Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf. | |
| CO2019007823A2 (es) | Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo | |
| UY33515A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ngf | |
| CO2021011648A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-il-33 | |
| MX2022006784A (es) | Formulaciones de anticuerpos anti-pd-l1. | |
| MX2023001160A (es) | Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo. | |
| CL2022001495A1 (es) | Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-cd20 x anti-cd3. | |
| CO2023014918A2 (es) | Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3 | |
| UY33652A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar) | |
| AR117607A1 (es) | Formulaciones de anticuerpo líquidas de alta concentración | |
| CO2026000834A2 (es) | Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-bcma x anti-cd3 | |
| CU20200015A7 (es) | Composición farmacéutica y kit que comprenden anticuerpos anti-tnf alpha | |
| AR125292A1 (es) | Formulaciones estabilizadas que contienen anticuerpos biespecíficosanti-muc16 x anti-cd3 | |
| CO2022009693A2 (es) | Formulación estable y de alta concentración del anticuerpo nimotuzumab | |
| CY1125584T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
| TN2012000342A1 (en) | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |